Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments

Monte Rosa Therapeutics

17/03/2026 11:08

Overview

Biotechnology firm's Q4 collaboration revenue fell sharply yr/yr amid lower milestone payments

Q4 net loss widened as R&D expenses rose on MRT-8102 and other programs

Company completed $345 mln equity offering in Jan 2026, extending cash runway into 2029

Outlook

Monte Rosa expects to initiate multiple Phase 2 studies of MRT-8102 starting in H2 2026

Company anticipates readout of GFORCE-1 study in elevated CVD-risk subjects in H2 2026

Monte Rosa expects its cash position to fund operations and capital expenditures into 2029

Result Drivers

PIPELINE INVESTMENT - Higher R&D expenses driven by increased spending on MRT-8102 and other development programs

CLINICAL PROGRESS - Positive interim data for MRT-8102 showed rapid and durable CRP reductions and a favorable safety profile

LOWER MILESTONE PAYMENTS - Collaboration revenue declined due to lower milestone payments from partners

Company press release: ID:nGNX2T12ml

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$2.78 mln
Q4 Net Income
-$46.14 mln
Q4 Operating Expenses
$52.50 mln
Q4 Operating Income
-$49.72 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $32.50, about 98.8% above its March 16 closing price of $16.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)